Page last updated: 2024-09-03

gefitinib and triazoles

gefitinib has been researched along with triazoles in 20 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(triazoles)
Trials
(triazoles)
Recent Studies (post-2010) (triazoles)
5,2315662,91925,8082,25213,501

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (35.00)29.6817
2010's13 (65.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE1
Kaplow, R1
Ali, S; Barrett, N; Beresford, E; Coombes, RC; Hadjiminas, D; Jiang, J; Mansi, JL; Morrison, K; Peston, D; Polychronis, A; Shivapatham, D; Shousha, S; Singhal, H; Sinnett, HD; Slade, MJ; Vigushin, D1
Carlini, P; Ciccarese, M; Cognetti, F; Fabi, A; Felici, A; Ferretti, G; Milella, M; Nuzzo, C; Papaldo, P; Ruggeri, EM1
Clark, E; Detre, S; Dowsett, M; Llombart, A; Magill, P; Mayordomo, JI; Salter, J; Skene, A; Smith, IE; Walsh, G1
Bode, AM; Christov, K; Ericson, ME; Grubbs, CJ; Juliana, MM; Lubet, RA; Steele, VE; Szabo, E1
Belli, C; Giovannini, M; Gregorc, V; Villa, E1
Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C1
Beyer, A; Cai, WY; Elledge, R; Fuqua, S; Hilsenbeck, S; Huang, J; Massarweh, S; Rimawi, M; Sexton, K; Tham, YL; Tsimelzon, A; Weiss, H1
A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M1
Badve, SS; Carlson, RW; Gomez, HL; O'Neill, A; Sledge, GW; Vidaurre, T1
Bill, A; Famulok, M; Hannam, JS; Heukamp, LC; König, K; Schmitz, A1
Chen, Z; Li, Z; Liao, M; Lu, S; Niu, X; Shen, L; Shen, S; Yu, Y1
Hosoya, T; Imai, S; Kuzumaki, N; Morita, H; Nagasawa, A; Narita, M; Okada, Y; Okano, H; Okano, HJ; Suzuki, A; Suzuki, T; Yamamizu, K; Yamashita, JK1
Anandappa, G; Turner, NC1
Mehta, A; Tripathy, D1
Dowsett, M; Gao, Q; Garcia-Murillas, I; López-Knowles, E; Martin, LA; Segal, CV; Smith, I; Turner, NC1
Chen, Y; Ding, J; Geng, M; Huang, M; Shen, A; Shen, YY; Sun, J; Wang, L; Wang, X; Yang, X1
Basaran, G; Bogaerts, J; Cameron, D; Cufer, T; Debled, M; Dirix, L; Piccart, M; Thery, JC; Tjan-Heijnen, VC; Tryfonidis, K; Van den Weyngaert, D1
Bode, A; Grubbs, CJ; Juliana, MM; Lubet, RA; Moeinpour, F; Steele, VE1

Reviews

4 review(s) available for gefitinib and triazoles

ArticleYear
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
    European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:3

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Nitriles; Postmenopause; Quinazolines; Tamoxifen; Treatment Outcome; Triazoles

2005
Innovations in antineoplastic therapy.
    The Nursing clinics of North America, 2005, Volume: 40, Issue:1

    Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate

2005
Targeting receptor tyrosine kinases in HER2-negative breast cancer.
    Current opinion in oncology, 2013, Volume: 25, Issue:6

    Topics: Anastrozole; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Nitriles; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Treatment Outcome; Triazoles; Up-Regulation

2013
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
    Breast (Edinburgh, Scotland), 2014, Volume: 23, Issue:1

    Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles

2014

Trials

7 trial(s) available for gefitinib and triazoles

ArticleYear
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
    The Lancet. Oncology, 2005, Volume: 6, Issue:6

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; England; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Treatment Outcome; Triazoles; Ultrasonography

2005
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-01, Volume: 25, Issue:25

    Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Estradiol; Female; Gefitinib; Humans; Ki-67 Antigen; Mastectomy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Progesterone; Triazoles

2007
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-15, Volume: 16, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tissue Distribution; Treatment Outcome; Triazoles

2010
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
    Breast cancer research and treatment, 2011, Volume: 129, Issue:3

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cell Cycle; Cyclin D1; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Ki-67 Antigen; Male; Mitogen-Activated Protein Kinases; Neoadjuvant Therapy; Nitriles; Oncogene Protein v-akt; Proto-Oncogene Proteins; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Triazoles

2011
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
    Breast cancer research and treatment, 2012, Volume: 133, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles

2012
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
    Breast cancer research : BCR, 2014, Jun-30, Volume: 16, Issue:3

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Nitriles; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; TOR Serine-Threonine Kinases; Triazoles

2014
A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 53

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Early Termination of Clinical Trials; Female; Gefitinib; Humans; Middle Aged; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles

2016

Other Studies

9 other study(ies) available for gefitinib and triazoles

ArticleYear
Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Dec-10, Volume: 24, Issue:35

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Gefitinib; Humans; Isoenzymes; Lymphatic Metastasis; Middle Aged; Nitriles; Quinazolines; Triazoles

2006
Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bexarotene; Biomarkers, Tumor; Carcinogens; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Immunoenzyme Techniques; Mammary Neoplasms, Experimental; Methylnitrosourea; Phosphorylation; Quinazolines; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes; Triazoles

2008
Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case?
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents; Diagnosis, Differential; Drug Therapy, Combination; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Letrozole; Lung Neoplasms; Middle Aged; Nitriles; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Skin Neoplasms; Triazoles

2008
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
    Journal of the National Cancer Institute. Monographs, 2011, Volume: 2011, Issue:43

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles

2011
Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells.
    PloS one, 2012, Volume: 7, Issue:7

    Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Triazoles

2012
The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
    Lung cancer (Amsterdam, Netherlands), 2012, Volume: 78, Issue:3

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Estrogen Receptor alpha; Estrogen Receptor beta; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression; Humans; Inhibitory Concentration 50; Lung Neoplasms; MAP Kinase Signaling System; Nitriles; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Triazoles

2012
Multiple analyses of G-protein coupled receptor (GPCR) expression in the development of gefitinib-resistance in transforming non-small-cell lung cancer.
    PloS one, 2012, Volume: 7, Issue:10

    Topics: Adenosine A2 Receptor Antagonists; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fibroblasts; Gefitinib; Humans; Lung; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Pyrimidines; Quinazolines; Receptor, Adenosine A2A; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcriptome; Triazoles

2012
c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.
    Cancer research, 2015, Nov-01, Volume: 75, Issue:21

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gefitinib; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-myc; Pyridazines; Quinazolines; RNA Interference; RNA, Small Interfering; Triazoles; Xenograft Model Antitumor Assays

2015
Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.
    Oncology reports, 2018, Volume: 40, Issue:3

    Topics: Animals; Disease Models, Animal; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Heterocyclic Compounds, 3-Ring; Lapatinib; Male; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Triazoles

2018